← Markets

REGENXBIO Inc.

RGNX · NASDAQ

Market closed$9.89$-1.31 (-11.70%)After hours $9.90 · +0.10%

Key statistics

Previous close$11.20
Open$9.00
Day high$10.24
Day low$8.42
52-week high$16.19
52-week low$5.46
Market cap511.29M
Volume7.51M
Average volume2.39M
P/E ratio-1.77
Forward P/E—
EPS-5.60
Dividend yield0.00%

Market context

Why it moved

REGENXBIO shares fell sharply after the company announced and priced a $100 million underwritten public offering of common stock at $9.00 per share, raising significant dilution concerns among existing shareholders and compounding negative sentiment from a concurrent analyst downgrade to "strong sell."

Investing.comInvesting.comInvesting.comInvesting.comStocktwits

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026REGENXBIO tumbled sharply after pricing a $100 million underwritten public offering at $9.00 per share — a steep discount to its prior close — triggering dilution concerns that sent shares down nearly 12% on the session. The deal, managed by Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho, includes 10 million common shares and 1.1 million pre-funded warrants, with underwriters holding a 30-day option for an additional 1.67 million shares. Despite the selloff, the broader investor thesis remains intact: 10 of 11 analysts rate RGNX a Buy with a consensus price target of ~$24, as the company advances RGX-202 for Duchenne, seeks NAVSUNLI BLA resubmission for Hunter syndrome, and awaits key Q4 data readouts for its AbbVie-partnered eye disease programs.

-11.6964

July 17, 2026REGENXBIO shares plunged nearly 9% during the regular session and extended losses further after hours — down an additional ~14% — after the company announced a $100 million underwritten public stock offering, stoking sharp dilution concerns among investors. The deal, managed by Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho, includes an option for underwriters to purchase up to 15% more shares. Despite the selloff, 10 of 11 analysts still rate RGNX a Buy with an average price target of $24.36, and investor attention remains focused on upcoming DMD program catalysts, a Hunter syndrome treatment resubmission, and key Q4 data readouts for two AbbVie-partnered eye disease programs.

-8.7205

July 16, 2026REGENXBIO closed essentially flat as investors continued to digest last week's sharp selloff, when shares plunged nearly 10% after trial data raised concerns about its lead gene therapy candidate. The company remains under scrutiny for its heavy cash burn—quarterly operating cash flow of roughly -$76M against only ~$150M in cash reserves—though an ongoing patent lawsuit against Sarepta Therapeutics over Duchenne muscular dystrophy gene therapy Elevidys, with over $900M in potential damages, continues to serve as a key value catalyst. In after-hours trading, REGENXBIO shares are rebounding over 3%, outpacing a broadly flat healthcare sector.

-0.1627

July 15, 2026REGENXBIO shares declined, extending a rough stretch for the gene therapy company that saw its stock drop nearly 10% the prior week following concerns about its lead gene therapy program. The selloff comes amid a broader healthcare sector under pressure — the XLV ETF also closed lower — with biotech earnings expected to fall sharply in Q2 and macro headwinds including Iran-driven oil price surges and Fed rate hike uncertainty weighing on risk sentiment. In after-hours trading, RGNX is recovering modestly, up roughly 2.6%, though investors continue to weigh the company's heavy cash burn and limited near-term catalysts.

-3.6078

July 14, 2026REGENXBIO shares tumbled nearly 9% after trial data raised concerns about its lead gene therapy program, triggering aggressive selling that pushed the stock well below recent support levels. The sharp decline came against an already-challenging macro backdrop, with broader markets under pressure from renewed U.S.-Iran tensions and a risk-off tone weighing on small-cap biotech names despite Goldman Sachs recently calling the sector's fundamentals "extremely strong" and Jim Cramer labeling biotech "the hottest group in the market."

-8.6022

July 11, 2026REGENXBIO shares tumbled nearly 11% on well-above-average volume — more than 1.7x the daily average — as the gene therapy specialist faced a sharp selloff despite a broadly constructive day for biotech. The healthcare sector ETF (XLV) closed modestly lower while the S&P 500 edged up 0.42%, underscoring RGNX's significant underperformance. No specific company-level catalyst has been identified in available sources, but the move aligns with heightened volatility in smaller-cap gene therapy names even as mid-cap biotech peers attract renewed investor interest amid a broader rotation into the sector.

-10.8626

July 10, 2026REGENXBIO gained nearly 3% as biotech emerged as one of the market's hottest sectors amid a broader rotation out of technology. Jim Cramer and other market commentators highlighted biotech as a top pick, citing a more favorable FDA regulatory environment and an anticipated wave of M&A activity from cash-rich acquirers like Eli Lilly and Gilead. As a gene therapy company with late-stage pipeline assets, REGENXBIO fits the profile of a potential acquisition target that investors have been accumulating ahead of an expected surge in dealmaking.

2.7577

July 9, 2026REGENXBIO shares closed higher despite broader market headwinds from Middle East tensions and a risk-off environment that dragged major indexes lower. The biotech gained in a session where healthcare was among the market's resilient pockets, with Jim Cramer recently calling biotech "the hottest group in the market" and predicting a wave of M&A as the regulatory climate improves under new FDA leadership — a tailwind for companies like REGENXBIO with late-stage assets. Key catalysts include the dosing of the first patient in its Phase IIb/III NAAVIGATE trial for diabetic retinopathy, triggering a $100M AbbVie milestone payment, and plans for a Q3 2026 BLA submission for RGX-202 in Duchenne muscular dystrophy under accelerated approval. H.C. Wainwright maintains a Buy rating with a $26 price target.

1.3981

AllSci · July 17, 2026REGENXBIO Raises $100M for Gene Therapy PipelineInvesting.com · July 17, 2026Regenxbio prices $100m public offering at $9 per sharemarketscreener.com · July 17, 2026REGENXBIO Prices $100 Million Public OfferingStocksToTrade · July 17, 2026RGNX Stock Slides As $100M Offering And Legal Heat HitStocktwits · June 22, 2026RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio’s Hunter Syndrome TherapyPR Newswire · May 14, 2026REGENXBIO Reports First Quarter 2026 Financial Results and Operational HighlightsPR Newswire · March 5, 2026REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsNewMediaWire · January 28, 2026Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations
Mt Newswire · July 17, 2026REGENXBIO Prices $100 Million Public Offering
Benzinga · July 17, 2026REGENXBIO Prices Offering Of 10,003,889 Shares At $9.00 Per Share And 1,111,111 Pre-Funded Warrants At $8.9999 Per Warrant
Mt Newswire · July 16, 2026REGENXBIO Announces Proposed $100 Million Public Stock Offering
Benzinga · July 16, 2026REGENXBIO Plans To Commence $100M Common Stock Offering
Mt Newswire · July 2, 2026Regenxbio Insider Sold Shares Worth $688,756, According to a Recent SEC Filing
Mt Newswire · June 29, 2026REGENXBIO's Trial of Surabgene Lomparvovec in Diabetic Retinopathy Doses First Patient
Benzinga · June 29, 2026REGENXBIO Announces First Patient Dosed In Phase IIb/III NAAVIGATE Clinical Trial Of Investigational Surabgene Lomparvovec In Diabetic Retinopathy Using Suprachoroidal Delivery; REGENXBIO To Receive $100M From Abbvie For This Milestone
Benzinga · June 24, 2026REGENXBIO Completes Dosing In Its Confirmatory Study Of RGX-202 Gene Therapy For Duchenne Muscular Dystrophy

Peers

S&P 500SPX · $7,457.78-1.01%Regencell Bioscience Holdings LimitedRGC · $5.02+5.02%Vera Therapeutics, Inc.VERA · $38.50-1.58%Intellia Therapeutics, Inc.NTLA · $11.38-4.09%Sarepta Therapeutics, Inc.SRPT · $17.22-0.06%4D Molecular Therapeutics, Inc.FDMT · $10.99+1.38%Tourmaline Oil Corp.TRMLF · $44.56+0.39%Precigen, Inc.PGEN · $4.950.00%Kamada Ltd.KMDA · $7.05+2.03%PureTech Health plcPRTC · $17.02-0.12%COMPASS Pathways plcCMPS · $12.35-0.64%Ionis Pharmaceuticals, Inc.IONS · $54.39-0.48%